Cannabis Science Inc (CBIS) 0.0720 $CBIS
Cannabis Science In Final Negotiations To Establish Its First Medical Cannabis Facilities In Canada
PR Newswire - Thu Aug 07, 10:55AM CDT
Cannabis Science, Inc. (OTC-QB:CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture company for the purpose of acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada.
NTRR: Small Businesses Seize Big Opportunities in Cannabis Industry
Business Wire - Thu Aug 07, 9:16AM CDT
Rapidly evolving laws and enforcement have opened major opportunities in the U.S. cannabis sector for start-ups and small businesses. As new markets continue to emerge, Neutra Corp. (OTCBB: NTRR) is preparing to release new technology to capitalize on the nascent industry's "gold rush."
Cannabis Science, Inc. (CBIS) Encouraged by Florida Medical Cannabis Voter Support of 88 Percent; Florida Referendum in November Seen as Key Tipping Point
PR Newswire - Tue Aug 05, 10:23AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is encouraged by recent polling data by Quinnipiac University showing widespread support among voters in Florida for November's upcoming constitutional referendum on medical cannabis. The most recent study shows 88 percent of Florida voters are in favor of cannabis for medical uses.
Novus Acquisition & Development MMJ MedPlan Network Is A Contender
ACCESSWIRE - Tue Aug 05, 8:48AM CDT
Whitefish, MT / Aug 5, 2014 / As the Green Rush continues to gain political and cultural momentum across the country, shockwaves are being felt by all the primary players, from suppliers to patients, as the rapidly growing marijuana (MMJ) sector blows through each successive regulatory barrier. Even though 23 states (including DC) have enacted laws to legalize medical marijuana, the sector remains highly fragmented.
NTRR: Cannabis Boom Continues as New Markets Open
Business Wire - Tue Aug 05, 4:41AM CDT
As Neutra Corp. (OTCBB: NTRR) prepares to begin manufacturing and distributing its subsidiary's groundbreaking new vapor pen product, demand for cannabis-related products has taken another jump as recreational sales begin in the state of Washington.
Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy
PR Newswire Europe - Mon Aug 04, 8:25AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is announcing that through its wholly-owned subsidiary, Cannabis Science International Holding BV, has signed an agreement with the prestigious Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and efficacy studies of cannabinoid formulations performed in animal models for neurobehavioral diseases including sleep disorders.
Dr. Robert Melamede Joins Cannabis Professional University in Charlotte, NC at Business Seminar
PRWeb - Mon Aug 04, 5:37AM CDT
Cannabis Professional University announces that world-renowned medical cannabis research expert Dr. Robert Melamede, a Ph.D. in Molecular Biology and Biochemistry, has been added to the list of speakers at the Cannabis Business Seminar in Charlotte, North Carolina on Sunday August 3 from 9 am until 5 pm at the Sheraton Charlotte Airport Hotel.
Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
PR Newswire - Thu Jul 31, 10:07AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
CBIS Very Excited Over Federal Cannabis Legalization Efforts in U.S. House and Senate to Change Medical Cannabis Laws
PR Newswire - Wed Jul 30, 6:30AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change
PR Newswire - Tue Jul 29, 8:20AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds the Editorial Board of the New York Times for taking a strong position in opposition to current federal law on cannabis in its Sunday, July 27, 2014 publication. The New York Times also announces a series of upcoming editorials and articles this week exploring the issue called "High Time: An Editorial Series on Marijuana Legalization".
Legal Medical Marijuana Industry Goes Through Significant Changes as Progressive Regulatory Developments are Implemented - Company Aims to Take Advantage of Latest Developments
PR Newswire - Thu Jul 24, 12:10PM CDT
Cannabis and Legal Medical Marijuana companies adapt to latest industry developments with innovative operations and products to meet evolving expectations of both consumers and government regulations: OSL Holdings (OTC: OSLH), Hemp, Inc. (OTC: HEMP), FutureWorld Corp. (OTC: FWDG), Cannabis Science, Inc. (OTC: CBIS) and Terra Tech Corp. (OTC: TRTC)
Flagship Financial Year for Cannabis Science (CBIS:OTC.QB) Arrives Amid New Medical Marijuana Legislation
ACCESSWIRE - Thu Jul 24, 7:34AM CDT
BOCA RATON, FL / ACCESSWIRE / July 24, 2014 / In the fast growing small cap market of medical marijuana companies we believe Cannabis Science stands out among its peers such as American Green (ERBB: OTC.PK), Medical Marijuana, Inc (MJNA:OTC.PK), Hemp, Inc (HEMP:OTC.PK) and Abattis Bioceuticals Corp (ATTBF:OTC.QX)
Cannabis Science Appoints Dr. Roscoe M. Moore Jr., US Assistant Surgeon General (retired) for a Second Term on the Scientific Advisory Board as Special Senior Advisor to the Company
PR Newswire - Thu Jul 24, 6:56AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is pleased to announce the appointment of Dr. Roscoe M. Moore, Jr., formerly the US Assistant Surgeon General, for a second term on the scientific advisory board and as a special Senior Advisor to the Company. Among other contributions, Dr. Moore will be leading the Cannabis Science initiative in Africa.
NTRR: Cannabis Demand in California Could Top $2.1 Trillion
Business Wire - Tue Jul 22, 5:46AM CDT
Even as the state of Washington became the second to begin allowing recreational cannabis sales last week, Neutra Corp. (OTCBB: NTRR) and other business ancillary to the cannabis marketplace are already eying the potential for even larger marketplaces to the south. SF Weekly reported last week that demand for recreational cannabis in California could top an astounding $2.1 trillion.
CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial Officer, Robert Kane
PR Newswire - Fri Jul 18, 12:40PM CDT
Cannabis Science, Inc. (OTC:CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting bring attention to more evidence on the investor appetite to invest in quality companies.
Cannabis Capital Corp. (CBCA) Changes Name to Crown Baus Capital Corp., Better Reflecting Corporate Initiatives and Long-term Projects
PR Newswire - Thu Jul 17, 7:16AM CDT
Cannabis Capital Corp. (OTCBB: CBCA) is a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment/Media, Education, and Financial Services. The Company is pleased to announce that its Board of Directors has selected the name Crown Baus Capital Corp. to better reflect the company's existing and prospective ventures in these five business sectors. Simultaneous with this announcement of the corporate name change, the Company's website www.crownbaus.com has been launched.
Cannabis Science In Final Negotiations To Establish Its First Medical Cannabis Facilities In Canada
PR Newswire - Thu Aug 07, 10:55AM CDT
Cannabis Science, Inc. (OTC-QB:CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture company for the purpose of acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada.
NTRR: Small Businesses Seize Big Opportunities in Cannabis Industry
Business Wire - Thu Aug 07, 9:16AM CDT
Rapidly evolving laws and enforcement have opened major opportunities in the U.S. cannabis sector for start-ups and small businesses. As new markets continue to emerge, Neutra Corp. (OTCBB: NTRR) is preparing to release new technology to capitalize on the nascent industry's "gold rush."
Cannabis Science, Inc. (CBIS) Encouraged by Florida Medical Cannabis Voter Support of 88 Percent; Florida Referendum in November Seen as Key Tipping Point
PR Newswire - Tue Aug 05, 10:23AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is encouraged by recent polling data by Quinnipiac University showing widespread support among voters in Florida for November's upcoming constitutional referendum on medical cannabis. The most recent study shows 88 percent of Florida voters are in favor of cannabis for medical uses.
Novus Acquisition & Development MMJ MedPlan Network Is A Contender
ACCESSWIRE - Tue Aug 05, 8:48AM CDT
Whitefish, MT / Aug 5, 2014 / As the Green Rush continues to gain political and cultural momentum across the country, shockwaves are being felt by all the primary players, from suppliers to patients, as the rapidly growing marijuana (MMJ) sector blows through each successive regulatory barrier. Even though 23 states (including DC) have enacted laws to legalize medical marijuana, the sector remains highly fragmented.
NTRR: Cannabis Boom Continues as New Markets Open
Business Wire - Tue Aug 05, 4:41AM CDT
As Neutra Corp. (OTCBB: NTRR) prepares to begin manufacturing and distributing its subsidiary's groundbreaking new vapor pen product, demand for cannabis-related products has taken another jump as recreational sales begin in the state of Washington.
Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy
PR Newswire Europe - Mon Aug 04, 8:25AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is announcing that through its wholly-owned subsidiary, Cannabis Science International Holding BV, has signed an agreement with the prestigious Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and efficacy studies of cannabinoid formulations performed in animal models for neurobehavioral diseases including sleep disorders.
Dr. Robert Melamede Joins Cannabis Professional University in Charlotte, NC at Business Seminar
PRWeb - Mon Aug 04, 5:37AM CDT
Cannabis Professional University announces that world-renowned medical cannabis research expert Dr. Robert Melamede, a Ph.D. in Molecular Biology and Biochemistry, has been added to the list of speakers at the Cannabis Business Seminar in Charlotte, North Carolina on Sunday August 3 from 9 am until 5 pm at the Sheraton Charlotte Airport Hotel.
Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
PR Newswire - Thu Jul 31, 10:07AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
CBIS Very Excited Over Federal Cannabis Legalization Efforts in U.S. House and Senate to Change Medical Cannabis Laws
PR Newswire - Wed Jul 30, 6:30AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change
PR Newswire - Tue Jul 29, 8:20AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds the Editorial Board of the New York Times for taking a strong position in opposition to current federal law on cannabis in its Sunday, July 27, 2014 publication. The New York Times also announces a series of upcoming editorials and articles this week exploring the issue called "High Time: An Editorial Series on Marijuana Legalization".
Legal Medical Marijuana Industry Goes Through Significant Changes as Progressive Regulatory Developments are Implemented - Company Aims to Take Advantage of Latest Developments
PR Newswire - Thu Jul 24, 12:10PM CDT
Cannabis and Legal Medical Marijuana companies adapt to latest industry developments with innovative operations and products to meet evolving expectations of both consumers and government regulations: OSL Holdings (OTC: OSLH), Hemp, Inc. (OTC: HEMP), FutureWorld Corp. (OTC: FWDG), Cannabis Science, Inc. (OTC: CBIS) and Terra Tech Corp. (OTC: TRTC)
Flagship Financial Year for Cannabis Science (CBIS:OTC.QB) Arrives Amid New Medical Marijuana Legislation
ACCESSWIRE - Thu Jul 24, 7:34AM CDT
BOCA RATON, FL / ACCESSWIRE / July 24, 2014 / In the fast growing small cap market of medical marijuana companies we believe Cannabis Science stands out among its peers such as American Green (ERBB: OTC.PK), Medical Marijuana, Inc (MJNA:OTC.PK), Hemp, Inc (HEMP:OTC.PK) and Abattis Bioceuticals Corp (ATTBF:OTC.QX)
Cannabis Science Appoints Dr. Roscoe M. Moore Jr., US Assistant Surgeon General (retired) for a Second Term on the Scientific Advisory Board as Special Senior Advisor to the Company
PR Newswire - Thu Jul 24, 6:56AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is pleased to announce the appointment of Dr. Roscoe M. Moore, Jr., formerly the US Assistant Surgeon General, for a second term on the scientific advisory board and as a special Senior Advisor to the Company. Among other contributions, Dr. Moore will be leading the Cannabis Science initiative in Africa.
NTRR: Cannabis Demand in California Could Top $2.1 Trillion
Business Wire - Tue Jul 22, 5:46AM CDT
Even as the state of Washington became the second to begin allowing recreational cannabis sales last week, Neutra Corp. (OTCBB: NTRR) and other business ancillary to the cannabis marketplace are already eying the potential for even larger marketplaces to the south. SF Weekly reported last week that demand for recreational cannabis in California could top an astounding $2.1 trillion.
CFO Journal, part of the Wall Street Journal, addresses business challenges of cannabis industry in the article "Pot Industry Puts on a Tie" referencing Cannabis Science, Inc. (CBIS) Chief Financial Officer, Robert Kane
PR Newswire - Fri Jul 18, 12:40PM CDT
Cannabis Science, Inc. (OTC:CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting bring attention to more evidence on the investor appetite to invest in quality companies.
Cannabis Capital Corp. (CBCA) Changes Name to Crown Baus Capital Corp., Better Reflecting Corporate Initiatives and Long-term Projects
PR Newswire - Thu Jul 17, 7:16AM CDT
Cannabis Capital Corp. (OTCBB: CBCA) is a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment/Media, Education, and Financial Services. The Company is pleased to announce that its Board of Directors has selected the name Crown Baus Capital Corp. to better reflect the company's existing and prospective ventures in these five business sectors. Simultaneous with this announcement of the corporate name change, the Company's website www.crownbaus.com has been launched.
